Please assess the completion status of the following clinical trial:

Trial Title: EC PK in Women With Normal and Obese BMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18-45 years~* English-speaking~* BMI 18.5-24.9 kg/m2 or obese BMI 30.0-39.9 kg/m2~* Regular menstrual cycles~* No use of medroxyprogesterone acetate at least 6 months prior to study enrollment, unless resumption of two menstrual cycles~* No use of levonorgestrel intrauterine system (levonorgestrel-IUS), etonogestrel implant or combined hormonal contraception at least one month prior to the study and resumption of one menstrual cycle~* Women who are postpartum or post-abortion will be included if they have had at least one menstrual cycle since their last pregnancy~Exclusion Criteria:~* Prior allergic reaction to LNG-EC or UPA-EC~* Use of hormonal emergency contraception within the past month~* Women who are currently pregnant or who are currently breastfeeding~* History of cancer other than non-melanoma skin cancer~* Medical or surgical conditions or conditions requiring therapies known to impact sex steroid production or metabolism~  * Use of HAART therapy for management of HIV infection~ * Concomitant use of CYP3A4 inducers like rifampin, barbiturates, carbamazepine, lamotrigine, bosentan, felbamate, griseofulvin, oxcarbazepine, phenytoin, St. John's Wort and topiramate~* Current participation in any other trial of an investigational medicine or device in the three months leading up to this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Normal-BMI (Type: OTHER): Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
- Obese-BMI (Type: OTHER): Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.

Based on this trial design, predict the completion outcome and termination type (if applicable).